ProfileGDS5678 / 1430659_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 65% 65% 63% 64% 67% 66% 65% 64% 62% 65% 64% 65% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9215265
GSM967853U87-EV human glioblastoma xenograft - Control 23.8763665
GSM967854U87-EV human glioblastoma xenograft - Control 33.9062665
GSM967855U87-EV human glioblastoma xenograft - Control 43.7431863
GSM967856U87-EV human glioblastoma xenograft - Control 53.8208564
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0788967
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0665266
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.8924465
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.8176864
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.66362
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8926365
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8443164
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9386265
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.270969